Literature DB >> 3401639

Nisoldipine and perfusion of post-stenotic myocardium in conscious pigs with different degrees of concentric stenosis.

D J Duncker1, J P Heiligers, P R Saxena, P D Verdouw.   

Abstract

1. The effects of oral nisoldipine on the perfusion and wall function of a myocardial segment distal to a fixed coronary artery stenosis were studied in 2 groups of conscious pigs with different degrees of stenosis. In group 1 (n = 8) systolic wall thickening (SWT) of the post-stenotic segment was more than 15% (27 +/- 4%); in group 2 (n = 7) SWT was less than 10% (7 +/- 1%). 2. The systemic haemodynamic profiles at baseline and during nisoldipine were similar in both groups. Dose-titrations of nisoldipine (0.24 +/- 0.02 mg kg-1 and 0.47 +/- 0.04 mg kg-1) were performed to obtain increases in heart rate of 25% and 50%, respectively. These increases were accompanied by increases in cardiac output (up to 50%) and left ventricular (LV)dP/dt max (60%), while systemic vascular resistance (35%) and mean arterial blood pressure (10%) were reduced. Left ventricular systolic and end-diastolic blood pressure and stroke volume were not affected. 3. In both groups, nisoldipine caused increases in blood flow to the non-stenotic area which favoured the subepicardium more than the subendocardium. Blood flow to the post-stenotic area of group 1 was normal at baseline and was only slightly enhanced (preferentially to the subepicardium) by nisoldipine. In the post-stenotic area of group 2 transmural and subendocardial blood flow were lower at baseline compared to the control area. Nisoldipine did not affect subepicardial blood flow but reduced subendocardial blood flow. 4. In spite of the reflex-mediated positive chronotropic actions of nisoldipine, the acute poststenotic systolic wall thickening was not affected by nisoldipine in either group. 5. We conclude that, under the experimental conditions employed (concentric stenosis, no coronary collaterals and acute drug administration), nisoldipine does not have a useful effect on post-stenotic myocardial blood flow, particularly in animals with severe stenosis. In view of a possible resetting of the baroreceptors (subsiding of the tachycardia) with chronic treatment and the presence of eccentric stenosis in many patients, additional studies are warranted.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401639      PMCID: PMC1853934          DOI: 10.1111/j.1476-5381.1988.tb11518.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  27 in total

1.  Reduced regional myocardial perfusion in the presence of pharmacologic vasodilator reserve.

Authors:  J M Canty; F J Klocke
Journal:  Circulation       Date:  1985-02       Impact factor: 29.690

2.  Is nisoldipine capable of reducing left ventricular preload?

Authors:  P D Verdouw; C J Slager; R H Van Bremen; C M Verkeste
Journal:  Eur J Pharmacol       Date:  1984-02-10       Impact factor: 4.432

3.  Dissociation between epicardial and transmural function during acute myocardial ischemia.

Authors:  K P Gallagher; M C Stirling; M Choy; C A Szpunar; R A Gerren; M J Botham; J H Lemmer
Journal:  Circulation       Date:  1985-06       Impact factor: 29.690

4.  Salutary hemodynamic and sustained clinical beneficial effects of nisoldipine, a new calcium channel blocker, in patients with recurrent ischemia and severe heart failure.

Authors:  A Kimchi; A G Ellrodt; Y Charuzi; W Shell; G H Murata
Journal:  Am Heart J       Date:  1985-08       Impact factor: 4.749

5.  A dose-ranging, placebo-controlled, double-blind trial of nisoldipine in effort angina: duration and extent of antianginal effects.

Authors:  J Lam; B R Chaitman; P Crean; R Blum; D D Waters
Journal:  J Am Coll Cardiol       Date:  1985-08       Impact factor: 24.094

6.  Acute effects of intravenous nisoldipine on left ventricular function and coronary hemodynamics.

Authors:  P W Serruys; H Suryapranata; J Planellas; W Wijns; G L Vanhaleweyk; A Soward; B E Jaski; P G Hugenholtz
Journal:  Am J Cardiol       Date:  1985-07-01       Impact factor: 2.778

7.  Influence of heart rate on the effects of prenalterol on regional myocardial blood flow and function during coronary stenosis in dogs.

Authors:  A Berdeaux; C Bonhenry; P Duhazé; J F Giudicelli; C Thuillez
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

8.  Persistence of coronary vasodilator reserve despite functionally significant flow reduction.

Authors:  T Aversano; L C Becker
Journal:  Am J Physiol       Date:  1985-03

9.  N-(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654), a putative 5-HT1 agonist, causes constriction of arteriovenous anastomoses and dilatation of arterioles.

Authors:  P D Verdouw; H M Jennewein; J Mierau; P R Saxena
Journal:  Eur J Pharmacol       Date:  1985-01-08       Impact factor: 4.432

10.  Nifedipine prevents sympathetic vasoconstriction distal to severe coronary stenoses.

Authors:  G Heusch; A Deussen
Journal:  J Cardiovasc Pharmacol       Date:  1984 May-Jun       Impact factor: 3.105

View more
  4 in total

Review 1.  Regulation of Coronary Blood Flow.

Authors:  Adam G Goodwill; Gregory M Dick; Alexander M Kiel; Johnathan D Tune
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

2.  Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren.

Authors:  J P van Kats; L M Sassen; A H Danser; M P Polak; L K Soei; F H Derkx; M A Schalekamp; P D Verdouw
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  Late preconditioning against myocardial stunning. An endogenous protective mechanism that confers resistance to postischemic dysfunction 24 h after brief ischemia in conscious pigs.

Authors:  J Z Sun; X L Tang; A A Knowlton; S W Park; Y Qiu; R Bolli
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

4.  Myocardial glucose uptake after dobutamine stress in chronic hibernating swine myocardium.

Authors:  Edward O McFalls; Bilal Murad; Howard C Haspel; David Marx; Joseph Sikora; Herbert B Ward
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.